These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 390712)

  • 1. Factor VIII (antihemophilic globulin).
    Aronson DL
    Semin Thromb Hemost; 1979; 6(1):12-27. PubMed ID: 390712
    [No Abstract]   [Full Text] [Related]  

  • 2. Von Willebrand factor in high-purity factor VIII complex concentrates: chaperone protein or key to therapies? A meeting report.
    Federici AB; Mannucci PM; Marco P
    Haemophilia; 2008 Jan; 14(1):133-9. PubMed ID: 17941830
    [No Abstract]   [Full Text] [Related]  

  • 3. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 5. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihemophilic factor (factor VIII).
    Ratnoff OD
    Ann Intern Med; 1978 Mar; 88(3):403-9. PubMed ID: 343683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial.
    Hershgold EJ; Pool JG; Pappenhagen AR
    J Lab Clin Med; 1966 Jan; 67(1):23-32. PubMed ID: 5321736
    [No Abstract]   [Full Text] [Related]  

  • 8. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
    Carter NJ; Scott LJ
    Drugs; 2007; 67(10):1513-9. PubMed ID: 17600395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biological half-time of factor VIII antigen (antihemophilic globulin) in hemophilia A and in von Willebrand's disease].
    Uszyński L
    Acta Haematol Pol; 1974; 5(3):189-94. PubMed ID: 4546992
    [No Abstract]   [Full Text] [Related]  

  • 10. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.
    Brinkhous KM; Sandberg H; Garris JB; Mattsson C; Palm M; Griggs T; Read MS
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8752-6. PubMed ID: 3936044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of von Willebrand's Disease.
    Mannucci PM
    N Engl J Med; 2004 Aug; 351(7):683-94. PubMed ID: 15306670
    [No Abstract]   [Full Text] [Related]  

  • 12. [Oral administration of factor VIII or IX concentrate preparation].
    Sakuragawa N
    Rinsho Ketsueki; 1985 Jul; 26(7):1086-9. PubMed ID: 3932721
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates.
    Funk M; Ebener U; Kreuz W; Ehrenforth S
    Lancet; 1993 Oct; 342(8876):933-4. PubMed ID: 7692198
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma fractions rich in factor VIII.
    Deutsch E; Fischer M
    Bibl Haematol; 1968; 29():1094-103. PubMed ID: 5303857
    [No Abstract]   [Full Text] [Related]  

  • 16. Glycine-precipitated antihemophilic factor concentrates and their clinical use.
    Wagner RH; Roberts HR; Webster WP; Shanbrom E; Brinkhous KM
    Thromb Diath Haemorrh Suppl; 1968; 35():41-8. PubMed ID: 5761073
    [No Abstract]   [Full Text] [Related]  

  • 17. NIH conference. Factor VIII.
    Ann Intern Med; 1977 May; 86(5):598-616. PubMed ID: 300583
    [No Abstract]   [Full Text] [Related]  

  • 18. The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders.
    Jiménez-Yuste V; Kruse-Jarres R; Rangarajan S; Altisent C
    Thromb Haemost; 2016 Aug; 116 Suppl 1():S1. PubMed ID: 27528277
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preparatory procedures for obtaining antihemolytic globulin (factor VIII) by the cryoprecipitation method and its various properties].
    Lopaciuk S; Naleczyńska A; Klenowska Z; Daszyński J; Pawelski S
    Pol Tyg Lek; 1969 Jun; 24(22):826-9. PubMed ID: 5802316
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of hepatitis A after treatment with pasteurised factor VIII concentrates in children with haemophilia A and von Willebrand disease.
    Kreuz W; Klarmann D; Auerswald G; Auberger K; Gürtler L; Rabenau H; Doerr WD
    Lancet; 1993 Feb; 341(8842):446. PubMed ID: 8094219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.